Email Updates

Search form

You are here

3 MAY 2019 VOLUME 20 ISSUE 17

Media Coverage

  • Intensive remedial efforts by the Department of Health to keep people on HIV treatment have led to the US reversing plans to cut the President’s Emergency Plan for AIDS Relief’s (PEPFAR) funding.

    May 3, 2019
    IOL
  • In 1994, physician-researcher Bruce Walker was sure he’d stumbled upon the impossible. Despite being HIV positive, the patient in his office was healthy—and had been for at least a decade, all without the help of drugs. But in a year when AIDS would kill 35,000 people in the United States alone, all Walker’s patient wanted to know was when he would die, too.

    May 2, 2019
    General
    PBS
  • A report has shown how allocation of funds to tackle HIV/AIDS in counties is still low, with experts warning that the situation is hindering the achievement of universal healthcare.

    May 2, 2019
    General
    Standard Digital
  • An end to the AIDS epidemic could be in sight after a landmark study found men whose HIV infection was fully suppressed by antiretroviral drugs had no chance of infecting their partner.

    May 2, 2019
    The Guardian
  • An African-led first HIV vaccine trial has given hope to millions of people who will only need a few shots to be immunised against the virus. The clinical trial, running from 2018 to 2022 and dubbed PrEVacc, is being conducted in four African countries that include Zimbabwe as Africa takes the lead in the fight against the pandemic. The trial will be one of the highlights at the upcoming 10th conference on HIV science in Mexico.

    April 30, 2019
    Zimbabwe Daily
  • Activists from the group ACT UP Dublin gathered outside the Four Courts this morning in protest at the pharmaceutical giant Gilead blocking access to its anti-HIV medication, Truvada. The group demands that Gilead end its efforts to extend its expired patent and significantly drop the price where the patent is still in effect.

    April 30, 2019
    GCN
  • Although Salvador is 23 years old and lives halfway across the country, his parents back home in the Carolinas always know when he visits his doctor. He doesn’t even need to tell them: Their health insurance provider, which also covers his health care, does that for him. After each medical appointment, an explanation of benefits arrives at his parents’ place detailing every billable procedure, test, and prescription he received during the visit. So, whether Salvador likes it or not, his parents always have a sense of the state of his health.

    April 29, 2019
    Slate
  • The World Health Organization (WHO) estimates that transgender women are 49 times more likely to be affected by HIV than other populations. Because transgender women are particularly vulnerable to HIV infection, scientists are striving to understand how feminizing hormones impact the efficacy of HIV medication. Unfortunately, this community is also underrepresented when it comes to enrollment in pre-exposure prophylaxis (PrEP) trials.

    April 29, 2019
    Contagion Live
  • Long-acting injectable antiretroviral (ARV) treatment will likely finally become a reality for people living with HIV by the end of the year. ViiV Healthcare has applied to the Food and Drug Administration (FDA) for approval of a long-acting injectable formulation of Janssen’s rilpivirine (currently sold in daily oral pill form as Edurant) and ViiV’s cabotegravir, which is dosed every four weeks through an intramuscular injection (into the muscle, as opposed to under the skin) that requires a clinic visit.

    April 29, 2019
    POZ
  • Over the past few months, there's been national buzz around the Department of Health and Human Services plan to end the HIV epidemic in the U.S. by 2030. Federal officials have presented their preliminary strategies at several national conferences and meetings, including the March 2019 National HIV Prevention Conference in Atlanta.

    April 24, 2019
    General
    The BodyPro
  • Several US senators have asked the Health and Human Services Department to explain what, if any, steps are being taken to ensure that patents held by the federal government on an HIV prevention pill are properly licensed. The lawmakers also asked agency officials to demonstrate how they take into account whether medicines are affordable when considering licensing patents.

    April 24, 2019
    STAT

Published Research

Announcements